Phase 1 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You must be 18 years of age or older when you sign the consent form.
• You must be willing and able to understand and sign a consent form agreeing to take part.
• If you have cancer, you must have a confirmed diagnosis of one of these cancer types: pancreatic cancer (PDAC), non-small cell lung cancer, esophageal squamous cell carcinoma, cervical cancer, endometrial cancer, or ovarian cancer — and have had a CT or MRI scan within the past 12 weeks showing at least one area of active or remaining disease.
• Your recent blood test results (taken within 30 days before receiving the study drug) must show that your blood cell counts and organ function are within acceptable ranges, including your white blood cells, platelets, red blood cells, kidneys, and liver (confirm specific values with trial site).
• Your doctor must believe you are expected to live for at least 12 weeks.
• Your blood oxygen level must be at least 95% while breathing normal room air.
• Your heart's electrical activity (measured by an ECG) must be within normal ranges for specific intervals (confirm with trial site).
• You must be willing to avoid illegal drugs for one week before your PET scan and for a few days afterward.
• You must be willing to avoid donating blood for 4 weeks after receiving the study drug.
• You must not have taken part in another research study involving medication within the past 4 weeks (or a shorter period depending on the medication used).

Who may not be able to join:

• People who are unable to understand the trial or give informed consent, or who have a medical, psychological, or social condition that would prevent them from following the study rules.
• Women who are pregnant or breastfeeding; women who could become pregnant must have a negative pregnancy test within 72 hours before receiving the study drug.
• People who have had a severe allergic reaction (anaphylaxis) to a protein- or peptide-based medicine or imaging agent in the past.
• People with a known condition that could affect how the body processes the study drug, including chronic liver or kidney failure.
• People who would be unable to tolerate the procedures required by the study.
• People with cancer that has spread to the brain who need high doses of steroid medications (above a certain level) for at least 2 weeks before receiving the study drug (confirm specific dose threshold with trial site).
• People with a serious or uncontrolled medical condition that, in the doctor's opinion, could make participation risky or make the results harder to interpret.
• People who have had a significant heart or blood vessel problem within the past 6 months, such as a stroke, heart attack, unstable chest pain, or serious heart rhythm problems, or who have moderate-to-severe heart failure.
• People who have had another type of cancer (other than those being studied) that was active within the past 3 years — except for certain easily treated skin cancers or early-stage cancers that have been fully treated.
• People with an active autoimmune disease, though some mild or stable autoimmune conditions may still be eligible (confirm with trial site).
• People who have had major surgery within 4 weeks before receiving the study drug.

Important: Always verify eligibility with the trial site directly before applying.